https://www.selleckchem.com/pr....oducts/gsk3326595-ep
Thus, these candidates deserve special attention for future repurposing or further development as anti-HBV therapeutics.Significant variation in human papillomavirus (HPV) prevalence in oropharyngeal squamous cell carcinoma (OPSCC) across countries ranging from 11% in Brazil to 74% in New Zealand has been reported earlier. The aim of this study was to systematically review the most recently published studies on the occurrence of HPV in OPSCC globally. PubMed and Embase were systematically searched for articles assessing the
Like
Comment
Share
